ID   LX12B_HUMAN             Reviewed;         701 AA.
AC   O75342;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   15-MAR-2017, entry version 153.
DE   RecName: Full=Arachidonate 12-lipoxygenase, 12R-type;
DE            Short=12R-LOX;
DE            Short=12R-lipoxygenase;
DE            EC=1.13.11.-;
DE   AltName: Full=Epidermis-type lipoxygenase 12;
GN   Name=ALOX12B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Hair follicle;
RX   PubMed=9618483; DOI=10.1073/pnas.95.12.6744;
RA   Boeglin W.E., Kim R.B., Brash A.R.;
RT   "A 12R-lipoxygenase in human skin: mechanistic evidence, molecular
RT   cloning, and expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:6744-6749(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RC   TISSUE=B-cell;
RX   PubMed=9837935; DOI=10.1074/jbc.273.50.33540;
RA   Sun D., McDonnell M., Chen X.-S., Lakkis M.M., Li H., Isaacs S.N.,
RA   Elsea S.H., Patel P.I., Funk C.D.;
RT   "Human 12(R)-lipoxygenase and the mouse ortholog. Molecular cloning,
RT   expression, and gene chromosomal assignment.";
RL   J. Biol. Chem. 273:33540-33547(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11350124; DOI=10.1006/geno.2001.6519;
RA   Krieg P., Marks F., Fuerstenberger G.;
RT   "A gene cluster encoding human epidermis-type lipoxygenases at
RT   chromosome 17p13.1: cloning, physical mapping, and expression.";
RL   Genomics 73:323-330(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=21558561; DOI=10.1074/jbc.M111.251496;
RA   Zheng Y., Yin H., Boeglin W.E., Elias P.M., Crumrine D., Beier D.R.,
RA   Brash A.R.;
RT   "Lipoxygenases mediate the effect of essential fatty acid in skin
RT   barrier formation: a proposed role in releasing omega-hydroxyceramide
RT   for construction of the corneocyte lipid envelope.";
RL   J. Biol. Chem. 286:24046-24056(2011).
RN   [6]
RP   FUNCTION IN MUCUS PRODUCTION.
RX   PubMed=22441738; DOI=10.1183/09031936.00023111;
RA   Garcia-Verdugo I., BenMohamed F., Tattermusch S., Leduc D.,
RA   Charpigny G., Chignard M., Ollero M., Touqui L.;
RT   "A role for 12R-lipoxygenase in MUC5AC expression by respiratory
RT   epithelial cells.";
RL   Eur. Respir. J. 40:714-723(2012).
RN   [7]
RP   VARIANTS ARCI2 PRO-426 AND GLN-578.
RX   PubMed=11773004; DOI=10.1093/hmg/11.1.107;
RA   Jobard F., Lefevre C., Karaduman A., Blanchet-Bardon C., Emre S.,
RA   Weissenbach J., Ozguc M., Lathrop M., Prud'homme J.-F., Fischer J.;
RT   "Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated
RT   in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to
RT   chromosome 17p13.1.";
RL   Hum. Mol. Genet. 11:107-113(2002).
RN   [8]
RP   CHARACTERIZATION OF VARIANTS ARCI2 PRO-426 AND GLN-578.
RX   PubMed=15629692; DOI=10.1016/j.bbalip.2004.10.007;
RA   Yu Z., Schneider C., Boeglin W.E., Brash A.R.;
RT   "Mutations associated with a congenital form of ichthyosis (NCIE)
RT   inactivate the epidermal lipoxygenases 12R-LOX and eLOX3.";
RL   Biochim. Biophys. Acta 1686:238-247(2005).
RN   [9]
RP   VARIANTS ARCI2 PRO-24; TRP-114; SER-127; CYS-318; MET-383; LYS-416;
RP   HIS-488; CYS-521; PRO-664 AND LEU-679, AND CHARACTERIZATION OF
RP   VARIANTS ARCI2 HIS-488 AND PRO-664.
RX   PubMed=16116617; DOI=10.1002/humu.20236;
RA   Eckl K.M., Krieg P., Kuester W., Traupe H., Andre F., Wittstruck N.,
RA   Fuerstenberger G., Hennies H.C.;
RT   "Mutation spectrum and functional analysis of epidermis-type
RT   lipoxygenases in patients with autosomal recessive congenital
RT   ichthyosis.";
RL   Hum. Mutat. 26:351-361(2005).
RN   [10]
RP   VARIANTS ARCI2 LEU-195 AND GLU-382, AND CHARACTERIZATION OF VARIANTS
RP   ARCI2 LEU-195 AND GLU-382.
RX   PubMed=19131948; DOI=10.1038/jid.2008.409;
RA   Eckl K.M., de Juanes S., Kurtenbach J., Naetebus M., Lugassy J.,
RA   Oji V., Traupe H., Preil M.L., Martinez F., Smolle J., Harel A.,
RA   Krieg P., Sprecher E., Hennies H.C.;
RT   "Molecular analysis of 250 patients with autosomal recessive
RT   congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and
RT   allelic heterogeneity in ALOX12B.";
RL   J. Invest. Dermatol. 129:1421-1428(2009).
RN   [11]
RP   VARIANTS ARCI2 PHE-67; ASP-462; CYS-521; MET-527 AND GLU-597.
RX   PubMed=19890349; DOI=10.1038/jid.2009.346;
RA   Vahlquist A., Bygum A., Gaanemo A., Virtanen M., Hellstroem-Pigg M.,
RA   Strauss G., Brandrup F., Fischer J.;
RT   "Genotypic and clinical spectrum of self-improving collodion
RT   ichthyosis: ALOX12B, ALOXE3, and TGM1 mutations in Scandinavian
RT   patients.";
RL   J. Invest. Dermatol. 130:438-443(2010).
CC   -!- FUNCTION: Non-heme iron-containing dioxygenase that catalyzes the
CC       stereo-specific peroxidation of free and esterified
CC       polyunsaturated fatty acids generating a spectrum of bioactive
CC       lipid mediators. Mainly converts arachidonic acid to (12R)-
CC       hydroperoxyeicosatetraenoic acid/(12R)-HPETE and minor
CC       stereoisomers. In the skin, acts upstream of ALOXE3 on the
CC       lineolate moiety of esterified omega-hydroxyacyl-sphingosine (EOS)
CC       ceramides to produce an epoxy-ketone derivative, a crucial step in
CC       the conjugation of omega-hydroxyceramide to membrane proteins.
CC       Therefore plays a crucial role in the synthesis of corneocytes
CC       lipid envelope and the establishment of the skin barrier to water
CC       loss. May also play a role in the regulation of the expression of
CC       airway mucins. {ECO:0000269|PubMed:21558561,
CC       ECO:0000269|PubMed:22441738, ECO:0000269|PubMed:9618483}.
CC   -!- CATALYTIC ACTIVITY: Arachidonate + O(2) = (5Z,8Z,10E,14Z)-(12R)-
CC       12-hydroperoxyicosa-5,8,10,14-tetraenoate.
CC       {ECO:0000269|PubMed:21558561}.
CC   -!- COFACTOR:
CC       Name=Fe cation; Xref=ChEBI:CHEBI:24875;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00726};
CC       Note=Binds 1 Fe cation per subunit. {ECO:0000255|PROSITE-
CC       ProRule:PRU00726};
CC   -!- PATHWAY: Lipid metabolism; hydroperoxy eicosatetraenoic acid
CC       biosynthesis. {ECO:0000269|PubMed:21558561}.
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000269|PubMed:21558561}.
CC   -!- INTERACTION:
CC       Q9BYJ1:ALOXE3; NbExp=2; IntAct=EBI-6925925, EBI-6925949;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|PROSITE-
CC       ProRule:PRU00726}.
CC   -!- TISSUE SPECIFICITY: Expressed in B-cells, hair follicles, foreskin
CC       keratinocytes and adult skin. Also expressed in psoriatic tissue.
CC       {ECO:0000269|PubMed:9618483}.
CC   -!- DISEASE: Ichthyosis, congenital, autosomal recessive 2 (ARCI2)
CC       [MIM:242100]: A form of autosomal recessive congenital ichthyosis,
CC       a disorder of keratinization with abnormal differentiation and
CC       desquamation of the epidermis, resulting in abnormal skin scaling
CC       over the whole body. The main skin phenotypes are lamellar
CC       ichthyosis (LI) and non-bullous congenital ichthyosiform
CC       erythroderma (NCIE), although phenotypic overlap within the same
CC       patient or among patients from the same family can occur. Lamellar
CC       ichthyosis is a condition often associated with an embedment in a
CC       collodion-like membrane at birth; skin scales later develop,
CC       covering the entire body surface. Non-bullous congenital
CC       ichthyosiform erythroderma characterized by fine whitish scaling
CC       on an erythrodermal background; larger brownish scales are present
CC       on the buttocks, neck and legs. {ECO:0000269|PubMed:11773004,
CC       ECO:0000269|PubMed:15629692, ECO:0000269|PubMed:16116617,
CC       ECO:0000269|PubMed:19131948, ECO:0000269|PubMed:19890349}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=about water - Issue 153
CC       of September 2013;
CC       URL="http://web.expasy.org/spotlight/back_issues/153/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF038461; AAC39770.1; -; mRNA.
DR   EMBL; AF059250; AAC79680.1; -; mRNA.
DR   EMBL; AJ305026; CAC34520.1; -; Genomic_DNA.
DR   EMBL; AJ305027; CAC34520.1; JOINED; Genomic_DNA.
DR   EMBL; BC041058; AAH41058.1; -; mRNA.
DR   CCDS; CCDS11129.1; -.
DR   RefSeq; NP_001130.1; NM_001139.2.
DR   UniGene; Hs.136574; -.
DR   ProteinModelPortal; O75342; -.
DR   SMR; O75342; -.
DR   BioGrid; 106743; 16.
DR   IntAct; O75342; 3.
DR   STRING; 9606.ENSP00000315167; -.
DR   BindingDB; O75342; -.
DR   SwissLipids; SLP:000000655; -.
DR   iPTMnet; O75342; -.
DR   PhosphoSitePlus; O75342; -.
DR   BioMuta; ALOX12B; -.
DR   MaxQB; O75342; -.
DR   PaxDb; O75342; -.
DR   PeptideAtlas; O75342; -.
DR   PRIDE; O75342; -.
DR   Ensembl; ENST00000319144; ENSP00000315167; ENSG00000179477.
DR   GeneID; 242; -.
DR   KEGG; hsa:242; -.
DR   UCSC; uc002gjy.1; human.
DR   CTD; 242; -.
DR   DisGeNET; 242; -.
DR   GeneCards; ALOX12B; -.
DR   GeneReviews; ALOX12B; -.
DR   HGNC; HGNC:430; ALOX12B.
DR   HPA; HPA024002; -.
DR   MalaCards; ALOX12B; -.
DR   MIM; 242100; phenotype.
DR   MIM; 603741; gene.
DR   neXtProt; NX_O75342; -.
DR   OpenTargets; ENSG00000179477; -.
DR   Orphanet; 79394; Congenital non-bullous ichthyosiform erythroderma.
DR   Orphanet; 313; Lamellar ichthyosis.
DR   Orphanet; 281122; Self-healing collodion baby.
DR   PharmGKB; PA24722; -.
DR   eggNOG; ENOG410IF0U; Eukaryota.
DR   eggNOG; ENOG410YN4N; LUCA.
DR   GeneTree; ENSGT00550000074415; -.
DR   HOGENOM; HOG000234358; -.
DR   HOVERGEN; HBG005150; -.
DR   InParanoid; O75342; -.
DR   KO; K08021; -.
DR   OMA; HWTEDSF; -.
DR   OrthoDB; EOG091G04A4; -.
DR   PhylomeDB; O75342; -.
DR   TreeFam; TF105320; -.
DR   BRENDA; 1.13.11.31; 2681.
DR   Reactome; R-HSA-2142712; Synthesis of 12-eicosatetraenoic acid derivatives.
DR   UniPathway; UPA00222; -.
DR   UniPathway; UPA00881; -.
DR   GeneWiki; ALOX12B; -.
DR   GenomeRNAi; 242; -.
DR   PRO; PR:O75342; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000179477; -.
DR   CleanEx; HS_ALOX12B; -.
DR   Genevisible; O75342; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004052; F:arachidonate 12-lipoxygenase activity; IMP:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:1990136; F:linoleate 9S-lipoxygenase activity; ISS:UniProtKB.
DR   GO; GO:0016702; F:oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen; IDA:UniProtKB.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IMP:UniProtKB.
DR   GO; GO:0046513; P:ceramide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0051122; P:hepoxilin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0043651; P:linoleic acid metabolic process; ISS:UniProtKB.
DR   GO; GO:0019372; P:lipoxygenase pathway; IDA:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0070257; P:positive regulation of mucus secretion; IMP:UniProtKB.
DR   GO; GO:0006497; P:protein lipidation; ISS:UniProtKB.
DR   GO; GO:0006665; P:sphingolipid metabolic process; IDA:UniProtKB.
DR   Gene3D; 2.60.60.20; -; 1.
DR   InterPro; IPR000907; LipOase.
DR   InterPro; IPR013819; LipOase_C.
DR   InterPro; IPR020834; LipOase_CS.
DR   InterPro; IPR020833; LipOase_Fe_BS.
DR   InterPro; IPR001885; LipOase_mml.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   PANTHER; PTHR11771; PTHR11771; 1.
DR   Pfam; PF00305; Lipoxygenase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PRINTS; PR00087; LIPOXYGENASE.
DR   PRINTS; PR00467; MAMLPOXGNASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF48484; SSF48484; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   PROSITE; PS00711; LIPOXYGENASE_1; 1.
DR   PROSITE; PS00081; LIPOXYGENASE_2; 1.
DR   PROSITE; PS51393; LIPOXYGENASE_3; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Cytoplasm; Dioxygenase; Disease mutation;
KW   Fatty acid metabolism; Ichthyosis; Iron; Lipid metabolism;
KW   Metal-binding; Oxidoreductase; Polymorphism; Reference proteome.
FT   CHAIN         1    701       Arachidonate 12-lipoxygenase, 12R-type.
FT                                /FTId=PRO_0000220689.
FT   DOMAIN        2    119       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   DOMAIN      120    701       Lipoxygenase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       398    398       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       403    403       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       578    578       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       582    582       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       701    701       Iron; via carboxylate; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00726}.
FT   VARIANT      24     24       L -> P (in ARCI2; dbSNP:rs201575829).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069545.
FT   VARIANT      67     67       I -> F (in ARCI2; dbSNP:rs397514533).
FT                                {ECO:0000269|PubMed:19890349}.
FT                                /FTId=VAR_069546.
FT   VARIANT      94     94       G -> S (in dbSNP:rs8077661).
FT                                /FTId=VAR_050000.
FT   VARIANT     114    114       R -> W (in ARCI2; dbSNP:rs397514526).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069547.
FT   VARIANT     127    127       P -> S (in ARCI2; dbSNP:rs72842957).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069548.
FT   VARIANT     195    195       F -> L (in ARCI2; complete loss of the
FT                                enzyme activity; dbSNP:rs200516538).
FT                                {ECO:0000269|PubMed:19131948}.
FT                                /FTId=VAR_069549.
FT   VARIANT     318    318       Y -> C (in ARCI2).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069550.
FT   VARIANT     382    382       K -> E (in ARCI2; complete loss of the
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:19131948}.
FT                                /FTId=VAR_069551.
FT   VARIANT     383    383       T -> M (in ARCI2; dbSNP:rs760428119).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069552.
FT   VARIANT     416    416       N -> K (in ARCI2).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069553.
FT   VARIANT     426    426       L -> P (in ARCI2; complete loss of the
FT                                enzyme activity; dbSNP:rs137853023).
FT                                {ECO:0000269|PubMed:11773004,
FT                                ECO:0000269|PubMed:15629692}.
FT                                /FTId=VAR_015173.
FT   VARIANT     462    462       G -> D (in ARCI2; dbSNP:rs774958790).
FT                                {ECO:0000269|PubMed:19890349}.
FT                                /FTId=VAR_069554.
FT   VARIANT     488    488       R -> H (in ARCI2; complete loss of the
FT                                enzyme activity; dbSNP:rs763468558).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069555.
FT   VARIANT     521    521       Y -> C (in ARCI2; dbSNP:rs199766569).
FT                                {ECO:0000269|PubMed:16116617,
FT                                ECO:0000269|PubMed:19890349}.
FT                                /FTId=VAR_069556.
FT   VARIANT     527    527       V -> M (in ARCI2; dbSNP:rs199545653).
FT                                {ECO:0000269|PubMed:19890349}.
FT                                /FTId=VAR_069557.
FT   VARIANT     578    578       H -> Q (in ARCI2; complete loss of the
FT                                enzyme activity; dbSNP:rs137853024).
FT                                {ECO:0000269|PubMed:11773004,
FT                                ECO:0000269|PubMed:15629692}.
FT                                /FTId=VAR_015174.
FT   VARIANT     597    597       A -> E (in ARCI2; dbSNP:rs752509098).
FT                                {ECO:0000269|PubMed:19890349}.
FT                                /FTId=VAR_069558.
FT   VARIANT     664    664       A -> P (in ARCI2; complete loss of the
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069559.
FT   VARIANT     679    679       R -> L (in ARCI2; dbSNP:rs397514528).
FT                                {ECO:0000269|PubMed:16116617}.
FT                                /FTId=VAR_069560.
SQ   SEQUENCE   701 AA;  80356 MW;  C334075759F8B077 CRC64;
     MATYKVRVAT GTDLLSGTRD SISLTIVGTQ GESHKQLLNH FGRDFATGAV GQYTVQCPQD
     LGELIIIRLH KERYAFFPKD PWYCNYVQIC APNGRIYHFP AYQWMDGYET LALREATGKT
     TADDSLPVLL EHRKEEIRAK QDFYHWRVFL PGLPSYVHIP SYRPPVRRHR NPNRPEWNGY
     IPGFPILINF KATKFLNLNL RYSFLKTASF FVRLGPMALA FKVRGLLDCK HSWKRLKDIR
     KIFPGKKSVV SEYVAEHWAE DTFFGYQYLN GVNPGLIRRC TRIPDKFPVT DDMVAPFLGE
     GTCLQAELEK GNIYLADYRI MEGIPTVELS GRKQHHCAPL CLLHFGPEGK MMPIAIQLSQ
     TPGPDCPIFL PSDSEWDWLL AKTWVRYAEF YSHEAIAHLL ETHLIAEAFC LALLRNLPMC
     HPLYKLLIPH TRYTVQINSI GRAVLLNEGG LSAKGMSLGV EGFAGVMVRA LSELTYDSLY
     LPNDFVERGV QDLPGYYYRD DSLAVWNALE KYVTEIITYY YPSDAAVEGD PELQSWVQEI
     FKECLLGRES SGFPRCLRTV PELIRYVTIV IYTCSAKHAA VNTGQMEFTA WMPNFPASMR
     NPPIQTKGLT TLETFMDTLP DVKTTCITLL VLWTLSREPD DRRPLGHFPD IHFVEEAPRR
     SIEAFRQRLN QISHDIRQRN KCLPIPYYYL DPVLIENSIS I
//
